Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jounce

- PMLiVE

Opdivo gets FDA green light to treat bladder cancer

BMS adds new US indication to its checkpoint inhibitor

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

Celgene building

Celgene pays $300m upfront for immunology start-up Delinia

Broadens its pipeline with autoimmune disease candidate due to start trials in 2018

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

- PMLiVE

Celgene scoops Socially Responsible Initiative prize at PMEA 2016

Lauded for 'inspirational' initiative that tackled real need in developing countries

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

- PMLiVE

NICE U-turn sees Celgene’s Imnovid backed for multiple myeloma

New data and a discount swayed the cost-effectiveness body

- PMLiVE

Bayer wins Company of the Year at PMEA 2016

Sees off strong competition from AbbVie, Celgene and Novartis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links